-
Henry Schein Q2 GAAP EPS $0.82, non-GAAP $1.27; raises FY2026 guidance
Q2 revenue $3.5B (+6.7% YoY); GAAP net income $94M vs $86M; non-GAAP net income $145M vs $135M.
-
Henry Schein elects William K. Daniel as Independent Chairman; Bergman retires
William K. Daniel elected Independent Chairman effective May 21, 2026.
-
Henry Schein Q1 GAAP EPS $0.92, non-GAAP $1.32; reaffirms 2026 guidance
Q1 GAAP diluted EPS $0.92 vs $0.88 YoY; non-GAAP diluted EPS $1.32 vs $1.15 YoY.
-
Henry Schein Q4 sales +7.7%, non-GAAP EPS $1.34; 2026 guide $5.23-$5.37
Q4 GAAP EPS $0.85 vs $0.74; non-GAAP EPS $1.34 vs $1.19; total sales $3.4B (+7.7% YoY, internal 4.9%).
-
Henry Schein names Frederick Lowery as CEO effective March 2, 2026; Bergman remains Chairman
Frederick Lowery (ex-Thermo Fisher EVP) succeeds Stanley Bergman as CEO; Bergman continues as Chairman.
-
Henry Schein Q3 2025 non-GAAP EPS $1.38 vs $1.22; raises FY guidance
Q3 GAAP EPS $0.84 vs $0.78; non-GAAP EPS $1.38 vs $1.22; revenue $3.3B up 5.2% YoY.
-
Henry Schein Q2 GAAP EPS $0.70 (down 12.5% YoY); maintains FY25 guidance
Q2 GAAP net income $86M ($0.70 diluted EPS) vs $104M ($0.80) YoY; non-GAAP EPS $1.10 vs $1.23.
-
Stanley M. Bergman to retire as Henry Schein CEO at end of 2025; will remain Chairman
Bergman to retire as CEO effective Dec 31, 2025, after 45 years at the company, over 35 as CEO.
-
Henry Schein closes $250M KKR investment; Dan Daniel joins board
KKR invested $250M for ~12% of HSIC common shares at ~$76.10/share in private placement.
-
Henry Schein Q1 GAAP EPS $0.88 (+22% YoY); non-GAAP EPS $1.15 (+4.5%); maintains FY guidance
Q1 net sales $3.2B; constant currency sales up 1.4% (2.0% ex-PPE/COVID test kits).
-
Henry Schein Q4 2024 non-GAAP EPS $1.19 vs $0.66; guides 2025 EPS $4.80-$4.94
Q4 revenue $3.2B (+5.8% YoY); non-GAAP diluted EPS $1.19 (prior year $0.66).
-
Henry Schein announces $250M KKR investment, preliminary Q4 EPS $1.19, and 2025 guidance
KKR to invest $250M at ~$76.10/share, becoming 12% common shareholder with board seats.
-
Henry Schein Q3 GAAP EPS $0.78, non-GAAP $1.22; raises FY2024 non-GAAP EPS guidance to $4.74-$4.82
Total net sales $3.2B, up 0.4% YoY; internal sales down 2.6% reflecting cyber incident recovery and lower PPE sales.
-
Henry Schein Q2 GAAP EPS $0.80 vs $1.06 YoY; lowers FY24 guidance, announces restructuring
Q2 total sales $3.1B (+1.1% YoY); internal sales down 2.4%.
-
Henry Schein Q1 sales $3.2B, GAAP EPS $0.72; tightens 2024 sales growth guidance to 8-10%
Q1 total sales $3.2B (+3.7% YoY); internal sales -1.8% due to cyber incident (300-400 bps drag) and lower glove pricing.
-
Henry Schein Q4 GAAP EPS $0.13, non-GAAP $0.66; guides 2024 EPS $5.00-$5.16
Q4 net sales $3.0B (-10.5% YoY); estimated $350M-$400M reduction from cybersecurity incident.
-
Henry Schein receives Nasdaq deficiency notice for delayed Q3 10-Q due to Oct cyber incident
Nasdaq notified HSIC on Nov 13, 2023 of non-compliance with Listing Rule 5250(c)(1) for missing Q3 10-Q filing deadline of Nov 14.
-
Henry Schein Q3 non-GAAP EPS $1.32; lowers FY guidance to $4.43-$4.71 on cyber incident and macro headwinds
Q3 GAAP diluted EPS $1.05, non-GAAP diluted EPS $1.32; revenue $3.2B (+3.1% YoY).
-
Henry Schein to webcast Q3 results Nov 13, update FY guidance after cyber incident
Q3 2023 earnings release and webcast scheduled for Nov 13 at 10 a.m. ET.
-
Henry Schein reports Oct 14 cyber incident disrupting manufacturing and distribution
Determined on Oct 14 that a portion of manufacturing/distribution systems experienced a cyber incident; systems taken offline.
-
Henry Schein Q2 GAAP EPS $1.06, Non-GAAP $1.31; Revenue $3.1B; Affirms FY Guidance
GAAP net income $140M ($1.06/diluted share) vs Q2 2022 $160M ($1.16); non-GAAP $173M ($1.31) vs $179M ($1.30).
-
Henry Schein secures new $750M term loan and amends $1B revolver, boosting total liquidity to $1.8B
New $750M unsecured term loan facility matures July 2026; for working capital, acquisitions, stock buybacks.
-
Henry Schein Q1 revenue down 3.8% to $3.1B; non-GAAP EPS $1.21 vs $1.44; lowers 2023 guidance to $5.18-$5.35
GAAP diluted EPS $0.91 vs $1.30; non-GAAP diluted EPS $1.21 vs $1.44.
-
Henry Schein Q4 non-GAAP EPS $1.21 beats year-ago $1.07; guides FY23 $5.25-$5.42
Q4 net sales $3.4B, +1.2% as reported; internal sales ex-PPE/COVID test kits +5.0% in local currencies.
-
Henry Schein reports record Q3 non-GAAP diluted EPS of $1.15; narrows FY2022 guidance
Q3 net sales $3.1B (-3.5% YoY); internal sales ex-PPE/COVID test kits +6.8% in local currencies.
-
Henry Schein posts record Q2 sales $3.0B, EPS $1.16; lowers full-year sales guidance
Q2 net sales $3.0B (+2.1% YoY); internal sales ex-PPE/COVID up 6.7% in local currencies.
-
Henry Schein Q1 record sales $3.2B (+8.7% YoY), EPS $1.30 beats prior year; reaffirms FY2022 guidance
Net sales $3.2B, +8.7% YoY; GAAP diluted EPS $1.30 vs $1.16 YoY.
-
Henry Schein reports record Q4 non-GAAP EPS $1.07, FY sales $12.4B; guides FY22 EPS $4.75–$4.91
Q4 sales $3.3B (+5.2% YoY); GAAP EPS $1.05, non-GAAP EPS $1.07 vs. $1.00 last year.